<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31077002</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>06</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>10</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-2592</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of clinical immunology</Title>
          <ISOAbbreviation>J Clin Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>CAPS and NLRP3.</ArticleTitle>
        <Pagination>
          <StartPage>277</StartPage>
          <EndPage>286</EndPage>
          <MedlinePgn>277-286</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-019-00638-z</ELocationID>
        <Abstract>
          <AbstractText>Cryopyrin-associated periodic syndrome (CAPS) is a rare inherited autoinflammatory disorder characterized by systemic, cutaneous, musculoskeletal, and central nervous system inflammation. Gain-of-function mutations in NLRP3 in CAPS patients lead to activation of the cryopyrin inflammasome, resulting in the inappropriate release of inflammatory cytokines including IL-1β and CAPS-related inflammatory symptoms. Several mechanisms have been identified that are important for the normal regulation of the cryopyrin inflammasome in order to prevent uncontrolled inflammation. Investigators have taken advantage of some of these pathways to develop and apply novel targeted therapies, which have resulted in improved quality of life for patients with this orphan disease.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Booshehri</LastName>
            <ForeName>Laela M</ForeName>
            <Initials>LM</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Allergy, Immunology, and Rheumatology, Rady Children's Hospital of San Diego, University of California, San Diego, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hoffman</LastName>
            <ForeName>Hal M</ForeName>
            <Initials>HM</Initials>
            <Identifier Source="ORCID">0000-0001-8609-2548</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Pediatric Allergy, Immunology, and Rheumatology, Rady Children's Hospital of San Diego, University of California, San Diego, San Diego, CA, USA. hahoffman@ucsd.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 AI052430</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL126703</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL140898</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <Acronym>WT_</Acronym>
            <Agency>Wellcome Trust</Agency>
            <Country>United Kingdom</Country>
          </Grant>
          <Grant>
            <GrantID>R01 DK113592</GrantID>
            <Acronym>DK</Acronym>
            <Agency>NIDDK NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 AI155869</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>05</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Immunol</MedlineTA>
        <NlmUniqueID>8102137</NlmUniqueID>
        <ISSNLinking>0271-9142</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058847">Inflammasomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000071199">NLR Family, Pyrin Domain-Containing 3 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C453881">NLRP3 protein, human</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="N">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000073659" MajorTopicYN="N">Gain of Function Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058847" MajorTopicYN="N">Inflammasomes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000071199" MajorTopicYN="N">NLR Family, Pyrin Domain-Containing 3 Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Familial cold autoinflammatory syndrome</Keyword>
        <Keyword MajorTopicYN="Y">Muckle–Wells syndrome</Keyword>
        <Keyword MajorTopicYN="Y">cryopyrin-associated periodic syndromes</Keyword>
        <Keyword MajorTopicYN="Y">inflammasome</Keyword>
        <Keyword MajorTopicYN="Y">neonatal onset multi-system inflammatory disease</Keyword>
      </KeywordList>
      <CoiStatement>Conflict of Interest: Dr. Hoffman has received speaking fees from Novartis, consulting fees from Novartis, SOBI, Regeneron, and IFM, and research funds from Glaxo Wellcome, Vertex, Burroughs Wellcome, and Jecure.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>3</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>5</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31077002</ArticleId>
        <ArticleId IdType="mid">NIHMS1529126</ArticleId>
        <ArticleId IdType="pmc">PMC8575304</ArticleId>
        <ArticleId IdType="doi">10.1007/s10875-019-00638-z</ArticleId>
        <ArticleId IdType="pii">10.1007/s10875-019-00638-z</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Kile RM, Rusk HA. A case of cold urticaria with an unusual family history.
JAMA
1940;114:1067–8.</Citation>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever.
J Allergy Clin Immunol
2001. 
October;108(4):615–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4321996</ArticleId>
            <ArticleId IdType="pubmed">11590390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome.
Q J Med
1962. 
April;31:235–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14476827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prieur AM, Griscelli C. [Chronic meningo-cutaneo-articular syndrome in children].
Revue du rhumatisme et des maladies osteo-articulaires
1980. 
November;47(11):645–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7444307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hassink SG, Goldsmith DP. Neonatal onset multisystem inflammatory disease.
Arthritis Rheum
1983. 
May;26(5):668–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6847730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aksentijevich I, C P, Remmers EF, Mueller JL, Le J, Kolodner RD, et al.
The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model.
Arthritis Rheum
2007. 
April;56(4):1273–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4321998</ArticleId>
            <ArticleId IdType="pubmed">17393462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cuisset L, Jeru I, Dumont B, Fabre A, Cochet E, Le Bozec J, et al.
Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France.
Annals of the rheumatic diseases
2011. 
March;70(3):495–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21109514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Gregory SG, Mueller JL, Tresierras M, Broide DH, Wanderer AA, et al.
Fine structure mapping of CIAS1: identification of an ancestral haplotype and a common FCAS mutation, L353P.
Hum Genet
2003. 
February;112(2):209–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12522564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neven B, Marvillet I, Terrada C, Ferster A, Boddaert N, Couloignier V, et al.
Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome.
Arthritis Rheum
2010. 
January;62(1):258–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20039428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients’ lives.
Current medical research and opinion
2008. 
June;24(6):1577–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18423104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gerbig AW, Dahinden CA, Mullis P, Hunziker T. Circadian elevation of IL-6 levels in Muckle-Wells syndrome: a disorder of the neuro-immune axis?
Q J Med
1998. 
July;91(7):489–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9797932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cekic S, Yalcinbayir O, Kilic SS. Ocular Involvement in Muckle-Wells Syndrome.
Ocular immunology and inflammation
2018. 
December
17:1–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Dollfus H, Hafner R, Hofmann HM, Russo RA, Denda L, Gonzales LD, et al.
Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood.
Archives of ophthalmology
2000. 
October;118(10):1386–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11030821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA).
Pediatric radiology
2007. 
February;37(2):145–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17136361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Rosengren S, Boyle DL, Cho JY, Nayar J, Mueller JL, et al.
Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.
Lancet
2004. 
November
13;364(9447):1779–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4321997</ArticleId>
            <ArticleId IdType="pubmed">15541451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, et al.
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.
The New England journal of medicine
2006. 
August
10;355(6):581–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4178954</ArticleId>
            <ArticleId IdType="pubmed">16899778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al.
Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.
Cell
1999. 
April
2;97(1):133–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10199409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aganna E, Martinon F, Hawkins PN, Ross JB, Swan DC, Booth DR, et al.
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis.
Arthritis Rheum
2002. 
September;46(9):2445–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12355493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dode C, Le Du N, Cuisset L, Letourneur F, Berthelot JM, Vaudour G, et al.
New mutations of CIAS1 that are responsible for Muckle-Wells syndrome and familial cold urticaria: a novel mutation underlies both syndromes.
Am J Hum Genet
2002. 
June;70(6):1498–506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC379138</ArticleId>
            <ArticleId IdType="pubmed">11992256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome.
Nat Genet
2001. 
November;29(3):301–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4322000</ArticleId>
            <ArticleId IdType="pubmed">11687797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al.
De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases.
Arthritis Rheum
2002. 
December;46(12):3340–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4556432</ArticleId>
            <ArticleId IdType="pubmed">12483741</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al.
Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes.
Am J Hum Genet
2002. 
July;71(1):198–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC384980</ArticleId>
            <ArticleId IdType="pubmed">12032915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saito M, Nishikomori R, Kambe N, Fujisawa A, Tanizaki H, Takeichi K, et al.
Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients.
Blood
2008. 
February
15;111(4):2132–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18063752</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGeough MD, Wree A, Inzaugarat ME, Haimovich A, Johnson CD, Pena CA, et al.
TNF regulates transcription of NLRP3 inflammasome components and inflammatory molecules in cryopyrinopathies.
The Journal of clinical investigation
2017. 
December
1;127(12):4488–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5707143</ArticleId>
            <ArticleId IdType="pubmed">29130929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Touitou I, Lesage S, McDermott M, Cuisset L, Hoffman H, Dode C, et al.
Infevers: an evolving mutation database for auto-inflammatory syndromes.
Hum Mutat
2004. 
September;24(3):194–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15300846</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner JB, Verma D, Endres T, Broderick L, de Jesus AA, Hofer F, et al.
Clinical and Molecular Phenotypes of Low-Penetrance Variants of NLRP3: Diagnostic and Therapeutic Challenges.
Arthritis &amp; rheumatology
2017. 
November;69(11):2233–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28692792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verma D, Lerm M, Blomgran Julinder R, Eriksson P, Soderkvist P, Sarndahl E. Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases?
Arthritis Rheum
2008. 
March;58(3):888–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18311798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al.
The NLR gene family: a standard nomenclature.
Immunity
2008. 
March;28(3):285–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2630772</ArticleId>
            <ArticleId IdType="pubmed">18341998</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broderick L, De Nardo D, Franklin BS, Hoffman HM, Latz E. The inflammasomes and autoinflammatory syndromes.
Annual review of pathology
2015;10:395–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25423351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srinivasula SM, Poyet JL, Razmara M, Datta P, Zhang Z, Alnemri ES. The PYRIN-CARD protein ASC is an activating adaptor for caspase-1.
J Biol Chem
2002. 
June
14;277(24):21119–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11967258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dowds TA, Masumoto J, Zhu L, Inohara N, Nunez G. Cryopyrin-induced interleukin 1beta secretion in monocytic cells: enhanced activity of disease-associated mutants and requirement for ASC.
J Biol Chem
2004. 
May
21;279(21):21924–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15020601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gumucio DL, Diaz A, Schaner P, Richards N, Babcock C, Schaller M, et al.
Fire and ICE: the role of pyrin domain-containing proteins in inflammation and apoptosis.
Clin Exp Rheumatol
2002. 
Jul-Aug;20(4 Suppl 26):S45–53.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12371636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al-Garawi A, et al.
PYPAF1, a PYRIN-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-kappa B.
J Biol Chem
2002. 
March
29;277(13):11570–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11786556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masumoto J, Taniguchi S, Ayukawa K, Sarvotham H, Kishino T, Niikawa N, et al.
ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells.
J Biol Chem
1999. 
November
26;274(48):33835–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10567338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baroja-Mazo A, Martin-Sanchez F, Gomez AI, Martinez CM, Amores-Iniesta J, Compan V, et al.
The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response.
Nat Immunol
2014. 
August;15(8):738–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24952504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al.
The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation.
Nat Immunol
2014. 
August;15(8):727–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4116676</ArticleId>
            <ArticleId IdType="pubmed">24952505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes.
Nat Rev Immunol
2013. 
June;13(6):397–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3807999</ArticleId>
            <ArticleId IdType="pubmed">23702978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kayagaki N, Stowe IB, Lee BL, O’Rourke K, Anderson K, Warming S, et al.
Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.
Nature
2015. 
October
29;526(7575):666–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26375259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells.
Infect Immun
2005. 
April;73(4):1907–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1087413</ArticleId>
            <ArticleId IdType="pubmed">15784530</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He WT, Wan H, Hu L, Chen P, Wang X, Huang Z, et al.
Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion.
Cell Res
2015. 
December;25(12):1285–98.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4670995</ArticleId>
            <ArticleId IdType="pubmed">26611636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi J, Zhao Y, Wang K, Shi X, Wang Y, Huang H, et al.
Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.
Nature
2015. 
October
29;526(7575):660–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26375003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation.
Cell Microbiol
2003. 
September;5(9):581–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12925128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inohara N, Ogura Y, Nunez G. Nods: a family of cytosolic proteins that regulate the host response to pathogens.
Curr Opin Microbiol
2002. 
February;5(1):76–80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11834373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbera-Cremades M, Baroja-Mazo A, Gomez AI, Machado F, Di Virgilio F, Pelegrin P. P2X7 receptor-stimulation causes fever via PGE2 and IL-1beta release.
FASEB J
2012. 
July;26(7):2951–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22490780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y, Hara H, Nunez G. Mechanism and Regulation of NLRP3 Inflammasome Activation.
Trends Biochem Sci
2016. 
December;41(12):1012–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5123939</ArticleId>
            <ArticleId IdType="pubmed">27669650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, et al.
New mitochondrial DNA synthesis enables NLRP3 inflammasome activation.
Nature
2018. 
August;560(7717):198–203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6329306</ArticleId>
            <ArticleId IdType="pubmed">30046112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haneklaus M, O’Neil JD, Clark AR, Masters SL, O’Neill LAJ. The RNA-binding protein Tristetraprolin (TTP) is a critical negative regulator of the NLRP3 inflammasome.
J Biol Chem
2017. 
April
28;292(17):6869–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5409458</ArticleId>
            <ArticleId IdType="pubmed">28302726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neudecker V, Haneklaus M, Jensen O, Khailova L, Masterson JC, Tye H, et al.
Myeloid-derived miR-223 regulates intestinal inflammation via repression of the NLRP3 inflammasome.
The Journal of experimental medicine
2017. 
June
5;214(6):1737–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5460990</ArticleId>
            <ArticleId IdType="pubmed">28487310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song N, Liu ZS, Xue W, Bai ZF, Wang QY, Dai J, et al.
NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation.
Molecular cell
2017. 
October
5;68(1):185–97
e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28943315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stutz A, Kolbe CC, Stahl R, Horvath GL, Franklin BS, van Ray O, et al.
NLRP3 inflammasome assembly is regulated by phosphorylation of the pyrin domain.
The Journal of experimental medicine
2017. 
June
5;214(6):1725–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5460996</ArticleId>
            <ArticleId IdType="pubmed">28465465</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Cuellar E, Tsuchiya K, Hara H, Fang R, Sakai S, Kawamura I, et al.
Cutting edge: nitric oxide inhibits the NLRP3 inflammasome.
J Immunol
2012. 
December
1;189(11):5113–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23100513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juliana C, Fernandes-Alnemri T, Kang S, Farias A, Qin F, Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation.
J Biol Chem
2012. 
October
19;287(43):36617–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3476327</ArticleId>
            <ArticleId IdType="pubmed">22948162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kawashima A, Karasawa T, Tago K, Kimura H, Kamata R, Usui-Kawanishi F, et al.
ARIH2 Ubiquitinates NLRP3 and Negatively Regulates NLRP3 Inflammasome Activation in Macrophages.
J Immunol
2017. 
November
15;199(10):3614–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29021376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Song H, Liu B, Huai W, Yu Z, Wang W, Zhao J, et al.
The E3 ubiquitin ligase TRIM31 attenuates NLRP3 inflammasome activation by promoting proteasomal degradation of NLRP3.
Nature communications
2016. 
December
8;7:13727.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5155141</ArticleId>
            <ArticleId IdType="pubmed">27929086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dinarello CA. Overview of the interleukin-1 family of ligands and receptors.
Seminars in immunology
2013. 
December
15;25(6):389–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24275600</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder.
Immunity
2004. 
March;20(3):319–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15030775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tassi S, Carta S, Delfino L, Caorsi R, Martini A, Gattorno M, et al.
Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion.
Proceedings of the National Academy of Sciences of the United States of America
2010. 
May
25;107(21):9789–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2906851</ArticleId>
            <ArticleId IdType="pubmed">20445104</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosengren S, Mueller JL, Anderson JP, Niehaus BL, Misaghi A, Anderson S, et al.
Monocytes from familial cold autoinflammatory syndrome patients are activated by mild hypothermia.
J Allergy Clin Immunol
2007. 
April;119(4):991–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4322003</ArticleId>
            <ArticleId IdType="pubmed">17320940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, et al.
Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.
Immunity
2009. 
June
19;30(6):875–87.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2759865</ArticleId>
            <ArticleId IdType="pubmed">19501000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meng G, Zhang F, Fuss I, Kitani A, Strober W. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.
Immunity
2009. 
June
19;30(6):860–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2764254</ArticleId>
            <ArticleId IdType="pubmed">19501001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, et al.
Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice.
PloS one
2012;7(4):e35979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3338787</ArticleId>
            <ArticleId IdType="pubmed">22558291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brydges SD, Broderick L, McGeough MD, Pena CA, Mueller JL, Hoffman HM. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.
The Journal of clinical investigation
2013. 
November;123(11):4695–705.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3809806</ArticleId>
            <ArticleId IdType="pubmed">24084736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGeough MD, Pena CA, Mueller JL, Pociask DA, Broderick L, Hoffman HM, et al.
Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models.
J Immunol
2012. 
September
15;189(6):2707–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3495128</ArticleId>
            <ArticleId IdType="pubmed">22904305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wree A, McGeough MD, Inzaugarat ME, Eguchi A, Schuster S, Johnson CD, et al.
NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL-17 and TNF in mice.
Hepatology
2017. 
September
13;67(2):736–49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5849484</ArticleId>
            <ArticleId IdType="pubmed">28902427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura Y, Franchi L, Kambe N, Meng G, Strober W, Nunez G. Critical role for mast cells in interleukin-1beta-driven skin inflammation associated with an activating mutation in the nlrp3 protein.
Immunity
2012. 
July
27;37(1):85–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3411177</ArticleId>
            <ArticleId IdType="pubmed">22819042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, et al.
Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS).
The Journal of experimental medicine
2011. 
March
14;208(3):519–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3058571</ArticleId>
            <ArticleId IdType="pubmed">21282379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ, et al.
Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome.
Proceedings of the National Academy of Sciences
2010. 
May
25, 2010;107(21):9801–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2906866</ArticleId>
            <ArticleId IdType="pubmed">20457915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.
The New England journal of medicine
2003. 
June
19;348(25):2583–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12815153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al.
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations.
Archives of dermatology
2006. 
December;142(12):1591–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17178985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ross JB, Finlayson LA, Klotz PJ, Langley RG, Gaudet R, Thompson K, et al.
Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up.
J Cutan Med Surg
2008. 
Jan-Feb;12(1):8–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18258152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ, Kavanaugh A, et al.
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.
Arthritis Rheum
2008. 
August;58(8):2443–52.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18668535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, et al.
Use of canakinumab in the cryopyrin-associated periodic syndrome.
The New England journal of medicine
2009. 
June
4;360(23):2416–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19494217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldbach-Mansky R
Current status of understanding the pathogenesis and management of patients with NOMID/CINCA.
Current rheumatology reports
2011. 
April;13(2):123–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3195512</ArticleId>
            <ArticleId IdType="pubmed">21538043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman HM, Throne ML, Amar NJ, Cartwright RC, Kivitz AJ, Soo Y, et al.
Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Clinical therapeutics
2012. 
October;34(10):2091–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23031624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuemmerle-Deschner J, Hofer F, Endres T, Kortus-Goetze B, Blank N, Weissbarth-Riedelet E, et al.
Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome.
Rheumatology
2016;55(4):689–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26667214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caorsi R, Lepore L, Zulian F, Alessio M, Stabile A, Insalaco A, et al.
The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age.
Arthritis research &amp; therapy
2013. 
February
26;15(1):R33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3672768</ArticleId>
            <ArticleId IdType="pubmed">23442610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, et al.
Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes.
BMC pharmacology &amp; toxicology
2013. 
August
5;14:40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3750485</ArticleId>
            <ArticleId IdType="pubmed">23915458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, Hockerman S, Jacobsen EJ, Alippe Y, Selness SR, Hope HR, et al.
Selective inhibition of the p38alpha MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals.
The Journal of experimental medicine
2018. 
May
7;215(5):1315–25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5940269</ArticleId>
            <ArticleId IdType="pubmed">29549113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stack JH, Beaumont K, Larsen PD, Straley KS, Henkel GW, Randle JC, et al.
IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients.
J Immunol
2005. 
August
15;175(4):2630–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16081838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coll RC, Robertson AA, Chae JJ, Higgins SC, Munoz-Planillo R, Inserra MC, et al.
A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
Nature medicine
2015. 
March;21(3):248–55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4392179</ArticleId>
            <ArticleId IdType="pubmed">25686105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al.
Recommendations for the management of autoinflammatory diseases.
Annals of the rheumatic diseases
2015. 
September;74(9):1636–44.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26109736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Milhavet F, Cuisset L, Hoffman HM, Slim R, El-Shanti H, Aksentijevich I, et al.
The infevers autoinflammatory mutation online registry: update with new genes and functions.
Hum Mutat
2008. 
June;29(6):803–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18409191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I. INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations.
Nucleic acids research
2003. 
January
1;31(1):282–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC165478</ArticleId>
            <ArticleId IdType="pubmed">12520003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Gijn ME, Ceccherini I, Shinar Y, Carbo EC, Slofstra M, Arostegui JI, et al.
New workflow for classification of genetic variants’ pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID).
Journal of medical genetics
2018. 
August;55(8):530–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29599418</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
